CN105492456B - 肽组合物 - Google Patents

肽组合物 Download PDF

Info

Publication number
CN105492456B
CN105492456B CN201480026843.7A CN201480026843A CN105492456B CN 105492456 B CN105492456 B CN 105492456B CN 201480026843 A CN201480026843 A CN 201480026843A CN 105492456 B CN105492456 B CN 105492456B
Authority
CN
China
Prior art keywords
arg
phe
cys
trp
cyclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480026843.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN105492456A (zh
Inventor
S·沙玛
L·H·T·范德普罗格
B·亨德森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RHYTHM METABOLIC Inc
Original Assignee
RHYTHM METABOLIC Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RHYTHM METABOLIC Inc filed Critical RHYTHM METABOLIC Inc
Priority to CN202410043113.3A priority Critical patent/CN118271400A/zh
Priority to CN202410043141.5A priority patent/CN118240012A/zh
Publication of CN105492456A publication Critical patent/CN105492456A/zh
Application granted granted Critical
Publication of CN105492456B publication Critical patent/CN105492456B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201480026843.7A 2013-03-15 2014-03-14 肽组合物 Active CN105492456B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202410043113.3A CN118271400A (zh) 2013-03-15 2014-03-14 肽组合物
CN202410043141.5A CN118240012A (zh) 2013-03-15 2014-03-14 肽组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361790469P 2013-03-15 2013-03-15
US61/790,469 2013-03-15
PCT/US2014/028590 WO2014144260A1 (en) 2013-03-15 2014-03-14 Peptide compositions

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202410043113.3A Division CN118271400A (zh) 2013-03-15 2014-03-14 肽组合物
CN202410043141.5A Division CN118240012A (zh) 2013-03-15 2014-03-14 肽组合物

Publications (2)

Publication Number Publication Date
CN105492456A CN105492456A (zh) 2016-04-13
CN105492456B true CN105492456B (zh) 2024-11-01

Family

ID=50588892

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201480026843.7A Active CN105492456B (zh) 2013-03-15 2014-03-14 肽组合物
CN202410043141.5A Pending CN118240012A (zh) 2013-03-15 2014-03-14 肽组合物
CN202410043113.3A Pending CN118271400A (zh) 2013-03-15 2014-03-14 肽组合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202410043141.5A Pending CN118240012A (zh) 2013-03-15 2014-03-14 肽组合物
CN202410043113.3A Pending CN118271400A (zh) 2013-03-15 2014-03-14 肽组合物

Country Status (10)

Country Link
US (4) US10196425B2 (https=)
EP (2) EP2970388B1 (https=)
JP (4) JP6622690B2 (https=)
CN (3) CN105492456B (https=)
AU (5) AU2014227712B2 (https=)
CA (1) CA2906694A1 (https=)
ES (1) ES2693761T3 (https=)
RU (2) RU2020120797A (https=)
TR (1) TR201815173T4 (https=)
WO (1) WO2014144260A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2862444A1 (en) 2011-12-29 2013-07-04 Rhythm Metabolic, Inc. Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
PL2970389T3 (pl) * 2013-03-15 2021-03-08 Rhythm Pharmaceuticals, Inc. Kompozycje farmaceutyczne
RU2020120797A (ru) 2013-03-15 2020-07-02 Ритм Фармасьютикалз, Инк. Пептидные композиции
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
MA43040A (fr) * 2015-09-30 2018-08-08 Univ Berlin Charite Méthode de traitement de troubles associés à la voie du récepteur de la mélanocortine 4
AU2017340816C1 (en) * 2016-10-04 2022-02-10 Dsm Ip Assets B.V. Melanocortin-1-receptor agonists
JP2020514365A (ja) * 2017-03-15 2020-05-21 ノヴォ ノルディスク アー／エス メラノコルチン４受容体に結合可能な二環式化合物
EP3773897A1 (en) 2018-04-06 2021-02-17 Rhythm Pharmaceuticals, Inc. Compositions for treating kidney disease
WO2020053414A1 (en) * 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists
EP4216979A4 (en) * 2020-09-24 2024-11-06 Rhythm Pharmaceuticals, Inc. Methods of treating melanocortin-4 receptor pathway-associated disorders
CN113332416B (zh) * 2021-05-17 2022-02-22 宁波大学 丙谷二肽在制备治疗非酒精性脂肪肝药物中的应用
CN113209270B (zh) * 2021-05-17 2022-02-22 宁波大学 丙谷二肽在制备防治急性肝衰竭药物中的应用
JP2024532294A (ja) * 2021-08-24 2024-09-05 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｍｃ４ｒアゴニストペプチド
CN116789802A (zh) * 2023-06-25 2023-09-22 湖北省农业科学院畜牧兽医研究所 一种山羊mc4r增强型突变体及其应用
CN120192363A (zh) * 2023-12-22 2025-06-24 上海多米瑞生物技术有限公司 多肽化合物、其药物组合物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101257916A (zh) * 2005-07-08 2008-09-03 研究及应用科学协会股份有限公司 黑皮质素受体配体
CN102458436A (zh) * 2009-06-08 2012-05-16 帕拉丁科技公司 黑皮质素受体特异性肽

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE109793T1 (de) * 1987-05-22 1994-08-15 University Patents Inc Lineare und zyklische analoge von alpha-msh- fragmenten mit ausserordentlicher wirkung.
US5731408A (en) 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
GB9827500D0 (en) * 1998-12-14 1999-02-10 Wapharm Ab Compounds for control of eating, growth and body weight
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
CZ2003584A3 (cs) * 2000-08-30 2003-08-13 F. Hoffmann-La Roche Ag Selektivní cyklické peptidy
US7345144B2 (en) * 2001-07-11 2008-03-18 Palatin Technologies, Inc. Cyclic peptides for treatment of cachexia
US7342089B2 (en) * 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
AU2002322466B2 (en) * 2001-07-11 2007-08-30 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
US7034004B2 (en) * 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
FR2851563B1 (fr) 2003-02-26 2005-04-22 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
FR2852957B1 (fr) 2003-03-31 2005-06-10 Sod Conseils Rech Applic Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament
WO2005000338A1 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Uses of melanocortin-3 receptor (mc3r) agonist peptides
CA2530024A1 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Melanocortin receptor 4(mc4) agonists and their uses
FR2862971B1 (fr) 2003-11-28 2006-03-24 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
US8343031B2 (en) * 2004-03-23 2013-01-01 Michael Gertner Obesity treatment systems
FR2872165B1 (fr) 2004-06-24 2006-09-22 Sod Conseils Rech Applic Nouveaux derives de pyrimido-benzimidazole
JP2009500426A (ja) 2005-07-08 2009-01-08 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス メラノコルチン受容体のリガンド
ES2618315T3 (es) 2007-05-25 2017-06-21 Ipsen Pharma S.A.S. Ligandos del receptor de melanocortina modificados con hidantoína
AR066175A1 (es) 2007-06-15 2009-08-05 Sod Conseils Rech Applic Ligandos del receptor de melanocortina de peptidos ciclicos
NZ585131A (en) 2007-11-05 2012-10-26 Ipsen Pharma Sas Use melanocortins to treat insulin sensitivity
TW201002340A (en) * 2008-06-09 2010-01-16 Palatin Technologies Inc Melanocortin receptor-specific peptides for treatment of obesity
UY32690A (es) * 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
BR112012002445A2 (pt) * 2009-08-05 2015-10-13 Ipsen Pharma Sas uso de um agonista do receptor 4 de melanocortina.
US9314509B2 (en) 2009-11-16 2016-04-19 Ipsen Pharma S.A.S. Pharmaceutical compositions of melanocortin receptor ligands
US20120226018A1 (en) 2009-11-16 2012-09-06 Ipsen Pharma, S.A.S. Process for the Synthesis of Ac-Arg-Cyclo(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2
CA2833676C (en) 2011-06-14 2019-04-23 Ipsen Pharma S.A.S. A sustained-release composition containing peptides as active ingredient
EP2705835A1 (en) 2012-06-08 2014-03-12 Ipsen Pharma S.A.S. Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
RU2020120797A (ru) * 2013-03-15 2020-07-02 Ритм Фармасьютикалз, Инк. Пептидные композиции
PL2970389T3 (pl) 2013-03-15 2021-03-08 Rhythm Pharmaceuticals, Inc. Kompozycje farmaceutyczne

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101257916A (zh) * 2005-07-08 2008-09-03 研究及应用科学协会股份有限公司 黑皮质素受体配体
CN102458436A (zh) * 2009-06-08 2012-05-16 帕拉丁科技公司 黑皮质素受体特异性肽

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Analogs of MTII, Lactam Derivatives of a-Melanotropin, Modified at the N-Terminus, and Their Selectivity at Human Melanocortin Receptors 3, 4, and 5";Maria A. Bednarek et al.;《Biochemical and Biophysical Research Communications》;19991231;第261卷;第209页右栏第2段-第210页左栏第2段 *

Also Published As

Publication number Publication date
EP3450449A3 (en) 2019-06-12
EP3450449A2 (en) 2019-03-06
JP2025102830A (ja) 2025-07-08
HK1220697A1 (en) 2017-05-12
JP2016516719A (ja) 2016-06-09
US10196425B2 (en) 2019-02-05
CA2906694A1 (en) 2014-09-18
ES2693761T3 (es) 2018-12-13
AU2021269411A1 (en) 2021-12-16
JP7654587B2 (ja) 2025-04-01
US10858399B2 (en) 2020-12-08
RU2725150C2 (ru) 2020-06-30
US20250188124A1 (en) 2025-06-12
CN118240012A (zh) 2024-06-25
WO2014144260A1 (en) 2014-09-18
JP2022084844A (ja) 2022-06-07
US12077612B2 (en) 2024-09-03
US20190092815A1 (en) 2019-03-28
TR201815173T4 (tr) 2018-11-21
US20210040155A1 (en) 2021-02-11
AU2020203353A1 (en) 2020-06-11
JP2019172693A (ja) 2019-10-10
RU2020120797A (ru) 2020-07-02
AU2014227712A1 (en) 2015-10-01
EP2970388B1 (en) 2018-07-25
EP2970388A1 (en) 2016-01-20
RU2015145593A (ru) 2017-04-24
JP6622690B2 (ja) 2019-12-18
AU2024200528A1 (en) 2024-02-15
AU2018256493A1 (en) 2018-11-22
US20160017001A1 (en) 2016-01-21
CN105492456A (zh) 2016-04-13
CN118271400A (zh) 2024-07-02
AU2014227712B2 (en) 2018-08-02
JP7046871B2 (ja) 2022-04-04

Similar Documents

Publication Publication Date Title
JP7654587B2 (ja) ペプチド組成物
JP2025004067A (ja) 医薬組成物
RU2381233C2 (ru) Агонисты рецептора меланокортина
US9096646B2 (en) CXCR4 receptor compounds
TWI364290B (en) Melanocortin receptor ligands modifled with hydantoin
JP2023078335A (ja) メラノコルチン－４受容体経路関連障害の治療方法
TW201102082A (en) Melanocortin receptor-specific peptides
TW201119668A (en) Peptidic GLP-2 agonists
TW200425908A (en) Somatostatin-dopamine chimeric analogs and uses thereof
US20240269230A1 (en) Cyclotides in combination with kappa opioid receptor ligands for ms therapy
HK40006194A (en) Peptide compositions
HK1220697B (en) Peptide compositions
US8080632B2 (en) Peptide mimics of melanocyte stimulating hormone

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant